A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Sponsor
Bristol-Myers Squibb
Study ID
NCT03195478
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Specified dose on specified days
  • Ipilimumab — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.

Key Dates

Start date
Aug 2, 2017
Status verified
Aug 2025
Primary completion
Jan 5, 2024
Completion
Jan 5, 2024

Study Design

Enrollment
37 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Nivo/Ipi Combination Therapy A
  • Experimental: Nivo/Ipi Combination Therapy B
  • Experimental: Nivo/Ipi Combination Therapy C
  • Experimental: Nivo/Ipi Combination Arm D

Primary Outcome Measure

Number of Participants With Adverse Events (AEs) in Part 1. [ Time Frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months) ]

Related coverage on Hipa.ai

Related Studies